Oralair, a sublingual grass pollen immunotherapy tablet, has demonstrated efficacy in seven placebo controlled clinical trials involving more than 2,500 patients.
Earlier in 2007, Stallergenes has licensed Canadian development, promotion and distribution rights for Oralair, Actair (Dust Mites allergies) and Stalair rBet v 1 tablet (birch pollen recombinant allergen) to Paladin.
Paladin president and CEO Jonathan Ross Goodman said they are excited for Canadian allergy sufferers to have an efficacious, safer and more convenient treatment option.